Indirect Modulation of Dopamine D 2 Receptors as Potential Pharmacotherapy for Schizophrenia: II. Glutamate (Ant)Agonists

Abstract

Spanish

French

OBJECTIVE:

To summarize the published preclinical and clinical data that suggest the possible use of glutamate receptor agonists or antagonists as novel antipsychotic agents.

DATA SOURCES:

Primary and review articles were identified by MEDLINE search (from 1966 to December 1999) and through secondary sources.

STUDY SELECTION AND DATA EXTRACTION:

All of the articles identified from the data sources were evaluated and all information deemed relevant was included.

DATA SYNTHESIS:

The standard antipsychotic drugs, whose clinical activity correlates with affinity for dopamine D₂ receptors, alleviate some of the positive symptoms of schizophrenia, but have limited impact on negative symptoms. Several lines of evidence implicate glutamate-receptor system dysfunction(s) in schizophrenia, either as causative or contributory factors. In addition, several standard antipsychotic drugs modulate glutamate or glutamate receptor activity, suggesting an alternative view of their mechanism of antipsychotic action. Preliminary studies have shown that drugs which modulate glutamate brain concentrations have positive effects in animal models of schizophrenia.

CONCLUSIONS:

A role for glutamate in the pathogenesis or pharmacotherapy of schizophrenia is suggested from anatomic (interactions between glutamatergic and dopaminergic systems in relevant brain regions), physiologic (implication of glutamate-receptor dysfunction), and pharmacologic (modulation of glutamate or glutamate receptors) evidence. Therefore, compounds that function at glutamate receptors might represent a novel approach to the treatment of the disease or to the amelioration of symptoms, either as monotherapy or as an adjunct to dopamine D₂ receptor antagonists.

Keywords

glutamate receptors antipsychotics schizophrenia

Get full access to this article

View all access options for this article.

References

Seeman

Bzowej

Guan

Bergeron

Reynolds

Bird

Human brain D₁ and D₂ dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1987;1:5–15.

Potter

Hollister

. Antipsychotic agents & lithium. In: Katzung

, ed. Basic & clinical pharmacology. 7th ed. Stamford, CT: Appleton & Lange, 1998:464–82.

Wachtel

Turski

. Glutamate: A new target in schizophrenia? Trends Pharmacol Sci 1990;11:219–20.

Meltzer

. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263–87.

Dixon

Fenix

Kim

Raffa

. Indirect modulation of dopamine D₂ receptors as potential pharmacotherapy for schizophrenia: I. adenosine agonists. Ann Pharmacother 1999;33:480–8.

Schizophrenia and other psychotic disorders. In: Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994:273–315.

Crismon

Dorson

. Schizophrenia. In: Dipiro

Talbert

Yee

Matzke

Wells

Posey

, eds. Pharmacotherapy, a pathophysiologic approach. 3rd ed. Stamford, CT: Appleton & Lange, 1997:1367–9.

Gottesman II. Schizophrenia genesis: the origins of madness. New York: WH Freeman and Co., 1991:1–9.

Jeste

del Carmen

Lohr

Wyatt

. Did schizophrenia exist before the eighteenth century? Compar Psychiatry 1985;26:493–503.

10.

Bark

. On the history of schizophrenia: Evidence of its existence before 1800. N Y State J Med 1988;88:374–83.

11.

Hare

. Schizophrenia as a recent disease. Br J Psychiatry 1988;153:521–31.

12.

Cooper

Sartorius

. Cultural and temporal variation in schizophrenia: A speculation on the importance of industrialization. Br J Psychiatry 1977;130:50–5.

13.

Hare

. Was insanity on the increase? The fifty-sixth Maudsley Lecture. Br J Psychiatry 1983;142:439–55.

14.

Bleuler

. Die Prognose der Dementia praecox (Schizophreniegruppe). Allgemeine Zeitschrift für Psychia 1908;65:436–64.

15.

Torrey

Bowler

Taylor

Gottesman II . Schizophrenia and manic—depressive disorder. New York: Basic Books, 1994:86–9.

16.

Hyde

Casanova

Kleinman

Weinberger

. Neuroanatomical and neurochemical pathology in schizophrenia. In: Tasman

Goldfinger

, eds. Review of psychiatry. Vol 10. Washington, DC: American Psychiatric Association Press, 1991:7–23.

17.

Yolken

Torrey

. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Revs 1995;8:131–45.

18.

Fernandez

Hewicker

Trautwein

Pohlenz

Liess

. Viral antigen distribution in the central nervous system of cattle persistently infected with bovine viral diarrhea virus. Veterinary Pathol 1989;26:26–32.

19.

Leonard

. Fundamentals of psychopharmacology. 2nd ed. Chichester, England: John Wiley & Sons, 1997:185–215.

20.

Lidsky

Yablonsky-Alter

Zuck

Banerjee

. Antipsychotic drug effects on glutamatergic activity. Brain Res 1997;764:46–52.

21.

Reynolds

. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 1992;13:116–21.

22.

Carlsson

Lindqvist

. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140–4.

23.

Weinberger

. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660–9.

24.

J-P

Duvoisin

. Review: Neurotransmitter receptors I. The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 1995;34:1–26.

25.

Helton

Tizzano

J P

Monn

Schoepp

Kallman

. LY354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 1997;36:1511–6.

26.

Moghaddam

Adams

. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281: 1349–52.

27.

Nieuwenhuys

. Chemoarchitecture of the brain. Berlin: Springer-Verlag, 1985:14–9.

28.

Mayer

Westbrook

Guthrie

. Voltage-dependent block by Mg²⁺ of NMDA responses in spinal cord neurones. Nature 1984;309: 261–3.

29.

Cooper

Bloom

Roth

. The biochemical basis of neuropharmacology. 7th ed. New York: Oxford University Press, 1996:182.

30.

Weickert

Kleinman

. The neuroanatomy and neurochemistry of schizophrenia. Psychiatric Clin North Am 1998;21:57–75.

31.

Tsai

Passani

Slusher

Carter

Baer

Kleinman

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829–36.

32.

Toru

. Biological research on schizophrenia. Psychiatric Clin Neurosci 1998;52(suppl):S170–2.

33.

Deakin

Slater

Simpson

Gilchrist

Skan

Royston

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989;52:1781–6.

34.

Ishimaru

Kurumaji

Toru

. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis. Biol Psychiatry 1994;35:84–95.

35.

Nishikawa

Takashima

Toru

. Increased [³H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 1983;40:245–50.

36.

Kegeles

Humaran

Mann

. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol Psychiatry 1998;44:382–98.

37.

Tamminga

. Glutamatergic aspects of schizophrenia. Br J Psychiatry 1999;37(suppl):12–5.

38.

Breier

. Cognitive deficit in schizophrenia and its neurochemical basis. Br J Psychiatry 1999;37(suppl):16–8.

39.

Kim

Kornhuber

Schmid-Burgk

Holzmüller

. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980;20:379–82.

40.

Bjerkenstedt

Edman

Hagenfeldt

Sedvall

Wiesel

. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 1985;147: 276–82.

41.

Macciardi

Lucca

Catalano

Marino

Zanardi

Smeraldi

. Amino acid patterns in schizophrenia: Some new findings. Psychiatr Res 1990;32:63–70.

42.

Gattaz

Beckmann

. Glutamate in schizophrenics and healthy controls. Archiv Psychia Nervenkr 1982;231:221–5.

43.

Korpi

Kaufmann

Marnela

Weinberger

. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res 1987;20:337–45.

44.

Perry

. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett 1982;28:81–5.

45.

Weinberger

. Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry 1999;45:395–402.

46.

Harrison

McLaughlin

Kerwin

. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 1991;337: 450–2.

47.

Eastwood

McDonald

Burnet

PWJ

Beckwith

Kerwin

R W

Harrison

. Decreased expression of mRNA encoding non-NMDA receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol Brain Res 1995;29:211–23.

48.

Breese

Freedman

Leonard

. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res 1995;674:82–90.

49.

Kornhuber

Mack-Burkhardt

Riederer

Hebenstreit

Reynolds

G P

Andrews

[³H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989;77:231–6.

50.

Noga

Hyde

Herman

Spurney

Bigelow

Weinberger

Glutamate receptors in the postmortem striatum of schizophrenic, suicide and control brains. Synapse 1997;26:168–76.

51.

Olney

Farber

. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998–1007.

52.

Bertolino

Nawroz

Mattay

Barnett

Duyn

Moonen

C T

Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 1996;153:1554–63.

53.

Allen

Young

. Phencyclidine-induced psychosis. Am J Psychiatry 1978;135:1081–4.

54.

Deutsch

Mastropaolo

Schwartz

Rosse

Morihisa

. A “glutamatergic hypothesis” of schizophrenia. Clin Neuropharmacol 1989;12:1–13.

55.

Javitt

. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 1987;9:12–35.

56.

Jentsch

Roth

. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20:201–25.

57.

Carlsson

Hansson

Waters

Carlsson

. Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications. Life Sci 1997;61:75–94.

58.

Carlsson

Hansson

Waters

Carlsson

. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry 1999;37(suppl):2–6.

59.

Carlsson

. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 1989;75:221–6.

60.

Svensson

Carlsson

. Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation. Neuropharmacology 1992;31:513–8.

61.

Banerjee

Zuck

Yablonsky-Alter

Lidsky

. Glutamate agonist activity: Implications for antipsychotic drug action and schizophrenia. Neuroreport 1995;6:2500–4.

62.

Ulas

Nguyen

Cotman

. Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. Neuroreport 1993;4:1049–51.

63.

Sulzer

Joyce

Lin

Geldwert

Haber

Hattori

Dopamine neurons make glutamatergic synapses in vitro. J Neurosci 1998;18:4588–602.

64.

Kaneko

Akiyama

Nagatsu

Mizuno

. Immunohistochemical demonstration of glutaminase in catecholaminergic and serotoninergic neurons of rat brain. Brain Res 1990;507:151–4.

65.

Sacaan

Bymaster

Schoepp

. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. J Neurochem 1992;59:245–51.

66.

Wigmore

Lacey

. Metabotropic glutamate receptors depress glutamate-mediated synaptic input to rat midbrain dopamine neurones in vitro. Br J Pharmacol 1998;123:667–74.

67.

Cepeda

Levine

. Aging reduces neostriatal responsiveness to N-methyl-D-aspartate and dopamine: an in vitro electrophysiological study. Neuroscience 1996;73:733–50.

68.

Healy

Meador-Woodruff

. Dopamine receptor gene expression in hippocampus is differentially regulated by the NMDA receptor antagonist MK-801. Eur J Pharmacol 1996;306:257–64.

69.

Yamamoto

Cooperman

. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994;14:4159–66.

70.

Tarazi

Florijn

Creese

. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 1996;128:371–9.

71.

Riederer

Lange

Kornhuber

Danielczyk

. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforschung 1992;42:265–8.

72.

Carlsson

. The dopamine theory revisited. In: Hirsch

Weinberger

, eds. Schizophrenia. Oxford: Blackwell Science, 1995:379–400.

73.

Roberts

Anderson

. Stimulatory effect of L-glutamate and related amino acids on (³H)dopamine release from rat striatum: an in vitro model for glutamate action. J Neurochem 1979;32:1539–45.

74.

Schwarcz

Creese

Coyle

Snyder

. Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature 1978;271:766–78.

75.

Smiley

J F

Williams

Szigeti

Goldman-Rakic

. Light and electron microscope characterization of dopamine-immunoreactive axon in human cerebral cortex. J Comp Neurol 1992;321:325–35.

76.

Halpain

Girault

Greengard

. Activation of NMDA receptors induces dephosphorylation of DAPPP-32 in striatal slices. Nature 1990;343:369–71.

77.

Goff

Wine

. Glutamate in schizophrenia: Clinical and research implications. Schizophr Res 1997;27:157–68.

78.

Kalivas

Duffy

Barrow

. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J Pharmacol Exp Ther 1989;251:378–87.

79.

Mrzljak

Bergson

Pappy

Huff

Levenson

Goldman-Rakic

. Localization of dopamine D₄ receptors in GABAergic neurons of the primate brain. Nature 1996;381:245–8.

80.

Grunze

HCR

Rainnie

Hasselmo

Barkai

Hearn

McCarley

NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996;16:2034–43.

81.

Daly

Moghaddam

. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 1993;152:61–4.

82.

Maura

Giardi

Raiteri

. Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. J Pharmacol Exp Ther 1988;247:680–4.

83.

Imperato

Honore

Jensen

. Dopamine release in the nucleus caudatus and accumbens is under glutamatergic control through non-NMDA receptors: A study in freely-moving rats. Brain Res 1990;530: 223–8.

84.

Youngren

Daly

Moghaddam

. Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. J Pharmacol Exp Ther 1992;262:289–93.

85.

Taber

Fibiger

. Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: Modulation by metabotropic glutamate receptors. J Neurosc 1995;15:3896–904.

86.

Tsai

van Kammen

Chen

Kelley

Grier

Coyle

. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry 1998;44:667–74.

87.

Grotta

Clark

Coull

Pettigrew

Mackay

Goldstein

Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a Phase Ia randomized trial. Stroke 1995;26:602–5.

88.

Herrling

. D -CPP-ene (SDZ EAA 494), a competitive NMDA antagonist: Results from animal models and first results in humans (abstract). Neuropsychopharmacology 1994;10(suppl):591S.

89.

Kristensen

Svensson

Gordh

. The NMDA-receptor antagonist CPP abolishes neurogenic ‘wind up pain’ after intrathecal administration in humans. Pain 1992;51:249–53.

90.

Krystal

Karper

Seibyl

J P

Freeman

Delaney

Brenner

. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine response. Arch Gen Psychiatry 1994;51:199–214.

91.

Kornhuber

. Presynaptic dopaminergic modulation of cortical input to the striatum. Life Sci 1986;39:669–74.

92.

Sherman

Hegwood

Baruah

Waziri

. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol Psychiatry 1991;30;1191–8.

93.

Halberstadt

. The phencyclidine—glutamate model of schizophrenia. Clin Neuropharmacol 1995;18:237–49.

94.

Javitt

Zukin

. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301–8.

95.

Kallman

. The genetic theory of schizophrenia: An analysis of 691 schizophrenic twin index families. Am J Psychiatry 1946;103:309–22.

96.

Heston

. Psychiatric disorders in foster home reared children of schizophrenic mothers. Br J Psychiatry 1966;112:819–25.

97.

Kety

Rosenthal

Wender

Schulsinger

Jacobsen

. The biological and adoptive families of adopted individuals who become schizophrenic. In: Wynne

Cromwell

Matthysse

, eds. The nature of schizophrenia. New York: John Wiley & Sons, 1978:25–37.

98.

Gottesman II Shields

. Schizophrenia: the epigenetic puzzle. Cambridge: Cambridge University Press, 1982.

99.

Farmer

McGuffin

Gottesman II . Twin concordance for DSM-III schizophrenia: Scrutinising the validity of the definition. Arch Gen Psychiatry 1987;44:634–41.

100.

Onstad

Skre

Torgersen

Kringlen

. Twin concordance for DSM-III-R schizophrenia. Acta Psychiatr Scand 1991;83:395–401.

101.

Kendler

McGuire

Gruenberg

O'Hare

Spellman

Walsh

. The Roscommon Family Study: I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry 1993;50: 527–40.

102.

Kety

Wender

Jacobsen

Ingraham

Jansson

Faber

. Mental illness in the biological and adoptive relatives of schizophrenic adoptees: Replication of the Copenhagen study in the rest of Denmark. Arch Gen Psychiatry 1994;51:442–55.

103.

Karayiorgou

Gogos

. A turning point in schizophrenia genetics. Neuron 1997;19:967–79.

104.

Deakin

Simpson

Slater

Hellewell

. Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia. J Psychopharmacol 1997;11:133–42.

105.

Beckwith

Stefanis

McLaughlin

Kerwin

. The expression of NMDA receptor subunits in schizophrenia postmortem human hippocampus (abstract). Schizophrenia Res 1995;15:54.

106.

Humphries

Virgo

Mortimer

Barnes

Hirsch

de Belleroche

. The expression of the N-methyl-D-aspartate receptor subunit is decreased in schizophrenia (abstract). Schizophrenia Res 1995;15:60.

107.

Collinge

Curtis

. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Br J Psychiatry 1991;159:857–9.

108.

Chen

AC-H

Kalsi

Brynjolfsson

Sigmundsson

Curtis

Butler

Exclusion of linkage between schizophrenia and the gene encoding a neutral amino acid glutamate/aspartate transporter, SLC1A5. Am J Med Genet 1997;74:50–2.

109.

Heresco-Levy

Silipo

Javitt

. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 1996;32:731–40.

110.

Waziri

. Glycine therapy of schizophrenia (letter). Biol Psychiatry 1988;23:210–1.

111.

Rosse

Theut

Banay-Schwartz

Leighton

Scarcella

Cohen

Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label, pilot study. Clin Neuropharmacol 1989;12:416–24.

112.

Rosse

Schwartz

Leighton

Davis

Deutsch

. An open-label trial of milacemide in schizophrenia: An NMDA intervention strategy. Clin Neuropharmacol 1990;13:348–54.

113.

Rosse

Schwartz

Davis

Deutsch

. An NMDA intervention strategy in schizophrenia with “low-dose” milacemide. Clin Neuropharmacol 1991;14:268–72.

114.

Rosse

Fay-McCarthy

Kendrick

Davis

Deutsch

. D-Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol 1996;19:444–50.

115.

Wickelgren

. A new route to treating schizophrenia? Science 1998;281:1264–5.

116.

Adams

Moghaddam

. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 1998;18:5545–54.

117.

Moghaddam

. Glutamate and schizophrenia. Sci & Med 1999;6:22–31.

118.

Battaglia

Monn

Schoepp

. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 1997;229:161–4.

119.

Schoepp

Johnson

Wright

Salhoff

Mayne

LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology 1997;36:1–11.

120.

Ögren

Goldstein

. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 1994;11:167–77.

121.

Toru

Kurumaji

Ishimaru

. Excitatory amino acids: Implications for psychiatric disorders research. Life Sci 1994;55:1683–99.

122.

Strous

Javitt

. The N-methyl-D-aspartate receptor and schizophrenia. Israel J Med Sci 1996;32:275–81.

123.

Kornhuber

Weller

. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997;41:135–44.

124.

Hirsch

Das

Garey

de Belleroche

. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Pharmacol Biochem Behav 1997;56:797–802.

125.

Tamminga

. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998;12:21–36.

126.

Conn

J-P

. Pharmacology and functions of metabotropic glutamate receptors. Ann Rev Pharmacol Toxicol 1997;37:205–37.

127.

Conn

. Metabotropic glutamate receptors. Sci & Med 1999;6:28–37.